What are the most common side effects of Tepezza (Teprotumumab)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The most common side effects of Tepezza (Teprotumumab) include hyperglycemia, muscle spasms, nausea, alopecia, diarrhea, tinnitus and hearing impairment, dysgeusia, headache, weight loss, nail disorders, and menstrual disorders. These side effects are associated with the use of Teprotumumab, a human monoclonal antibody inhibitor of IGF-IR, as reported in the 2024 study published in Ophthalmology 1. The study highlights that Teprotumumab treatment is not suitable for everyone, particularly those with inflammatory bowel disease, pregnancy, or pre-existing hearing loss.

  • Key side effects to monitor include:
    • Hyperglycemia, which is crucial for diabetic patients to closely monitor their glucose levels during treatment
    • Muscle spasms, which may affect the legs and back
    • Hearing impairment, including tinnitus, which can persist after treatment ends
    • Gastrointestinal symptoms like nausea and diarrhea
    • Dermatological effects such as alopecia and nail disorders It is essential for patients to report any persistent or severe side effects to their healthcare provider, as dose adjustments or supportive treatments may be necessary to manage these effects while continuing therapy 1.

From the FDA Drug Label

The most common adverse reactions (≥5%) that occurred at greater incidence in the TEPEZZA group than in the control group during the treatment period of Studies 1 and 2 are summarized in Table 1

Adverse ReactionsTEPEZZAN=84N (%)PlaceboN=86N (%)

  • Fatigue includes asthenia † Hyperglycemia includes blood glucose increase ‡ Hearing impairment including hearing loss (deafness, including sensorineural deafness, eustachian tube dysfunction, hyperacusis, hypoacusis, autophony and tinnitus) § Nail disorder (includes nail discoloration, nail disorder and onychoclasis) Muscle spasms21 (25%)6 (7%) Nausea14 (17%)8 (9%) Alopecia11 (13%)7 (8%) Diarrhea10 (12%)7 (9%) Fatigue*10 (12%)6 (7%) Hyperglycemia†8 (10%)1 (1%) Hearing impairment‡8 (10%)0 Dysgeusia7 (8%)0 Headache7 (8%)6 (7%) Dry skin7 (8%)0 Weight decreased5 (6%)0 Nail disorder§4 (5%)0

The most common side effects of Tepezza (Teprotumumab) are:

  • Muscle spasms (25%)
  • Nausea (17%)
  • Alopecia (13%)
  • Diarrhea (12%)
  • Fatigue (12%)
  • Hyperglycemia (10%)
  • Hearing impairment (10%)
  • Dysgeusia (8%)
  • Headache (8%)
  • Dry skin (8%)
  • Weight decreased (6%)
  • Nail disorder (5%) 2

From the Research

Common Side Effects of Tepezza (Teprotumumab)

The most common side effects of Tepezza (Teprotumumab) include:

  • Nausea
  • Diarrhoea
  • Muscle spasms
  • Hearing impairment
  • Dysgeusia
  • Headaches
  • Dry skin
  • Infusion reactions
  • Hyperglycaemia 3
  • Fatigue 4
  • Hair loss 4
  • Weight loss 4
  • Gastrointestinal disturbances 4
  • Menstrual changes 4

Serious Side Effects

Some patients may experience serious side effects, such as:

  • Sensorineural hearing loss 5, 4
  • Rapidly progressive cognitive decline 3
  • Encephalopathy 3

Management of Side Effects

It is essential to monitor patients for these side effects and manage them accordingly. For example, hyperglycemia can be managed by monitoring blood sugar levels and adjusting treatment as needed 4. Hearing changes can be monitored, and possible upcoming therapies can be reviewed 4.

Dose Adjustment

In some cases, dose adjustment may be necessary to minimize side effects. For example, a lower dose of teprotumumab (10 mg/kg) has been shown to be effective in reducing the severity of adverse events, including sensorineural hearing loss 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

The Adverse Effects Profile of Teprotumumab.

The Journal of clinical endocrinology and metabolism, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.